160 related articles for article (PubMed ID: 37574220)
1. Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
LeBlanc R; Mian H; Reece D; Su J; Masih-Khan E; Chu M; Jimenez-Zepeda V; Sebag M; Song K; Louzada M; Kotb R; Visram A; White D; Stakiw J; Reiman A; Aslam M; Bergstrom D; Kaedbey R; Gul E; Venner C
Eur J Haematol; 2023 Nov; 111(5):815-823. PubMed ID: 37574220
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
3. Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A; Venner CP; Masih-Khan E; Louzada M; LeBlanc R; Sebag M; Song K; Jimenez-Zepeda VH; Kotb R; Kardjadj M; Mian H; White D; Stakiw J; Aslam M; Reiman A; Gul E; Reece D
Curr Oncol; 2022 Mar; 29(3):1575-1582. PubMed ID: 35323332
[TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib.
Chen CC; Parikh K; Abouzaid S; Purnomo L; McGuiness CB; Hussein M; Wade RL
J Manag Care Spec Pharm; 2017 Feb; 23(2):236-246. PubMed ID: 28125372
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U; Romano A; Del Fabro V; Bellofiore C; Bulla A; Parisi MS; Leotta S; Gentile M; Cangialosi C; Vincelli I; Mineo G; Rossi M; Poidomani M; Uccello G; Maugeri C; Mannina D; Innao V; Di Raimondo F; Conticello C
Front Oncol; 2021; 11():624405. PubMed ID: 33763359
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
LeBlanc R; Mian H; Reece D; Masih-Khan E; Kardjadj M; Jimenez-Zepeda VH; McCurdy A; Song K; Sebag M; Louzada M; White D; Stakiw J; Kotb R; Reiman A; Aslam M; Gul E; Venner CP
Br J Haematol; 2022 Jul; 198(1):93-102. PubMed ID: 35383886
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma.
Abdallah AO; Mahmoudjafari Z; Ahmed N; Cui W; Shune L; McGuirk J; Mohan M; Mohyuddin GR; Afrough A; Alkharabsheh O; Atrash S
Eur J Haematol; 2023 Jun; 110(6):626-632. PubMed ID: 36752328
[TBL] [Abstract][Full Text] [Related]
10. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
Jelínek T; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Adamová D; Wróbel M; Mikula P; Jarkovský J; Diels J; Gatopoulou X; Veselá Š; Besson H; Brožová L; Ito T; Hájek R
Curr Med Res Opin; 2018 May; 34(5):775-783. PubMed ID: 29172760
[TBL] [Abstract][Full Text] [Related]
11. The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies.
Szabo AG; Thorsen J; Iversen KF; Levring MB; Helleberg C; Hermansen E; Bønløkke ST; Nielsen K; Teodorescu EM; Kurt E; Strandholdt CN; Vangsted AJ
EJHaem; 2023 Nov; 4(4):1006-1012. PubMed ID: 38024635
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
[TBL] [Abstract][Full Text] [Related]
14. Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy.
Minarik J; Radocha J; Jungova A; Straub J; Jelinek T; Pika T; Pour L; Pavlicek P; Harvanova L; Pospisilova L; Krhovska P; Novakova D; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Maisnar V; Hajek R
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291949
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
16. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide combinations are a safe and effective option after daratumumab failure.
Brioli A; Gengenbach L; Mancuso K; Binder M; Ernst T; Heidel FH; Stauch T; Zamagni E; Hilgendorf I; Hochhaus A; Engelhardt M; von Lilienfeld-Toal M
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6569-6574. PubMed ID: 36781500
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
19. New drugs in multiple myeloma - role of carfilzomib and pomalidomide.
Jurczyszyn A; Legieć W; Helbig G; Hus M; Kyrcz-Krzemień S; Skotnicki AB
Contemp Oncol (Pozn); 2014; 18(1):17-21. PubMed ID: 24876816
[TBL] [Abstract][Full Text] [Related]
20. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly.
Leleu X; Chari A; Richard S; Khurana M; Yusuf A; Usmani SZ
Expert Rev Hematol; 2021 Dec; 14(12):1049-1058. PubMed ID: 34546844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]